Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2

Diagnosis, Therapeutic Targets, and Molecular Mechanisms
Herausgeber: Nagaraju, Ganji Purnachandra; Vadde, Ramakrishna

• Gebundenes Buch

Produktbeschreibung

Description based on volume 2, published 2022.

---

Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.

Produktdetails

• Verlag: Elsevier Inc
• Seitenzahl: 398
• Erscheinungstermin: 1. April 2022
• Englisch
• Abmessung: 235mm x 191mm x 22mm
• Gewicht: 894g
• ISBN-13: 9780323988070
• ISBN-10: 0323988075
• Artikelnr.: 62535652

Inhaltsangabe

1. Hepatocellular carcinoma diagnosis2. Computational analysis of
prognosisrelated genes in liver cancer3. Computational approaches to
identify biomarkers, enzymes, and pathways of hepatocellular carcinoma4.
Ribonucleic acid sequence analysis in deciphering hepatocellular
carcinoma5. Hepatocarcinogenesis and the role of next-generation sequencing
in liver cancer6. Liver cancer: the tumor microenvironment and associated
pathways7. Metabolic pathway-based target therapy to hepatocellular
carcinoma: a computational approach8. Targeting ion channels in hepatic
cancer9. Tyrosine kinases: their role in hepatocellular carcinoma10. Role
of transcription factors in hepatocellular carcinoma11. Modulatory act of
diverse transcriptional factors in liver carcinoma12. Association of
specificity protein 1 with hepatocellular carcinoma13. Promising biomarkers
for liver cancer14. Molecular signaling and its role in drug resistance in
hepatocellular carcinomas15. Multidrug resistance, a major obstacle in
hepatocellular carcinoma treatment: challenges and future perspectives16.
Proliferative signaling pathways in hepatocellular carcinoma17. Targeting
angiogenesis in hepatocellular carcinoma18. Conventional and novel
biomarkers for the diagnosis and prognosis of liver cancer19. Updates on
the staging and treatment of hepatocellular carcinoma20. ROS-mediated
pathways: potential role in hepatocellular carcinoma biology and therapy21.
Dysregulated cell-signaling pathways in hepatocellular carcinoma: causes
and therapeutic options22. LKB1/STK11-mediated signal transduction in
hepatocellular carcinoma